Hospital Universitario de Valladolid -ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2024

  1. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789

2023

  1. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

2021

  1. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

    BMC Cancer, Vol. 21, Núm. 1

2017

  1. Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

    Clinical and Translational Oncology, Vol. 19, Núm. 12, pp. 1537-1542

  2. Reflections on the Implementation of Low-Dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain

    Archivos de Bronconeumologia, Vol. 53, Núm. 10, pp. 568-573

  3. Surgical treatment of low and intermediate grade lung net

    Journal of Thoracic Disease, Vol. 9, pp. S1435-S1441

2016

  1. Sumario ejecutivo de las recomendaciones SEPAR de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas

    Archivos de Bronconeumologia, Vol. 52, Núm. 7, pp. 378-388

2014

  1. Atypical carcinoid tumours of the lung: Prognostic factors and patterns of recurrence

    Thorax, Vol. 69, Núm. 7, pp. 648-653